AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02800525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-switched Nd:YAG laser
Description: Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
Study NCT03477006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
Study NCT02306993 — intervention group
Intervention type: OTHER
Intervention: Healthy volunteers without SCT
Description: Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
Study NCT02306993 — intervention group
Intervention type: OTHER
Intervention: Healthy volunteers with SCT
Description: Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
Study NCT01802710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological support
Study NCT01802710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study NCT02781610 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care IV antibiotic(s)
Description: IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
Study NCT02306993 — intervention group
Intervention type: OTHER
Intervention: Volunteers with SCD
Description: Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
Study NCT02735902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist or direct oral anticoagulant treatment
Description: The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg
Study NCT02735902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist or direct oral anticoagulant treatment
Description: The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg
Study NCT02735902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped.
Study NCT00897650 — intervention group
Intervention type: GENETIC
Intervention: DNA/RNA sequencing and expression levels
Description: Lung tumor tissue will be collected.
Study NCT00897650 — intervention group
Intervention type: GENETIC
Intervention: Protein expression analysis
Description: Lung tumor tissue will be collected.
Study NCT00897650 — intervention group
Intervention type: PROCEDURE
Intervention: Lung tumor biopsy
Description: Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
Study NCT00291486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
Study NCT00291486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)
Description: All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
Study NCT01600079 — intervention group
Intervention type: BIOLOGICAL
Intervention: ZOSTAVAX™
Description: ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
Study NCT00897650 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked for a venous blood sample
Study NCT03367195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 1 Omeprazole 20 mg capsules twice daily
Study NCT03367195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS2411
Description: 1 DLBS2411 caplet 250 mg, twice daily
Study NCT03367195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule of Omeprazole
Description: 1 placebo capsule of omeprazole, twice daily
Study NCT03367195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo caplet of DLBS2411
Description: 1 placebo caplet of DLBS2411, twice daily
Study NCT02873793 — intervention group
Intervention type: GENETIC
Intervention: Extraction of total RNA from healthy and tumour tissues
Study NCT04480658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)
Description: Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe
Study NCT00002913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00002913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00002913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00002913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT03483415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
Study NCT03483415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
Study NCT03483415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
Study NCT02226887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MESH
Description: 1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * We add the mesh between the edges of the defect during fascia closure.~  * The skin is sutured purse string style.~3. Post-Op~   * Hospital discharge after verification of normal digestive transit.
Study NCT02226887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NO MESH
Description: 1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * The skin is sutured purse string style.~Post-Op~- Hospital discharge after verification of normal digestive transit
Study NCT02226887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative Imaging
Description: Abdominal Tomography 1 year after ileostomy closure
Study NCT03903302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS1-Sodium Valproate
Description: Single and multiple dose evaluation of CS1
Study NCT02226887 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative Imaging
Description: Abdominal Tomography 1 year after ileostomy closure
Study NCT02226887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pre-operative Imaging
Description: Contrast study is used to ensure the integrity of the distal anastomosis
Study NCT02226887 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative Imaging
Description: Contrast study is used to ensure the integrity of the distal anastomosis
Study NCT02226887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test and C-reactive protein at 4th day
Description: All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
Study NCT02226887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Test and C-reactive protein at 4th day
Description: All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
Study NCT01630291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrode device
Description: Lacrimal gland stimulation
Study NCT02487862 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stress Reduction Protocol
Description: Stress Reduction Protocol
Study NCT00423449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
Study NCT00423449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
Study NCT00423449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based agent
Description: Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
Study NCT02699710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid will be administered orally as tablet at a single dose of 5 mg.
Study NCT02699710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
Study NCT02699710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
Study NCT02699710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole will be administered orally as tablet at a dose of 20 mg.
Study NCT01153724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744
Description: 10 mcg solution for oral inhalation
Study NCT01153724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 400 mg capsule
Study NCT00374933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
Description: Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Study NCT00374933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic delayed ADLI
Description: Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Study NCT00374933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic delayed activated donor lymphocyte infusion
Description: Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Study NCT01041820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Children will be exposed to a 10-week exercise intervention
Study NCT02628353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
Study NCT02628353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phenolic compound
Description: 1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
Study NCT02121249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renaissance, Mazor Robotics Ltd, Caesare, Israel
Description: Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
Study NCT02121249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free hand technique
Description: No specific device is necessary in the free hand technique
Study NCT03383510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climate friendly diet
Description: Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
Study NCT03383510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic diet
Description: Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
Study NCT03383510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climate friendly and organic diet
Description: The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
Study NCT03383510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Control diet)
Description: A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy.
Study NCT04168099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Description: Cefotaxime IV
Study NCT04168099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemifloxacin
Description: Gemifloxacin oral
Study NCT01166204 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT01966913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01966913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICE chemotherapy regimen
Description: Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
Study NCT00829114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETHINYL ESTRADIOL AND LEVOGESTREL
Description: 30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
Study NCT00828009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV
Study NCT00828009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide
Study NCT00828009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV
Study NCT00828009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV
Study NCT00828009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV
Study NCT00828009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
Study NCT02360904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
Study NCT01529424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 1
Study NCT01529424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 2
Study NCT01529424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 3
Study NCT03751215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
Study NCT02360904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
Study NCT05371340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg)
Description: Once-daily 500 mg Quercetin
Study NCT05371340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (500 mg)
Description: Once-daily 500 mg methylcellulose 9E4M)
Study NCT01347931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIOV System
Description: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
Study NCT00882531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: 0.25 mg/kg, 1 per day, 4 month of treatment
Study NCT00882531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03325166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study NCT03325166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03325166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03325166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02727348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic with or without femoral block
Description: Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
Study NCT02519205 — intervention group
Intervention type: OTHER
Intervention: Survey
Study NCT04269876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine Lipid Oil Concentrate
Description: Marine Lipid Oil Concentrate softgels
Study NCT04269876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Dietary Supplement capsules
Study NCT04269876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo softgels
Study NCT04269876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT00549445 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Description: 250 mg daily